All In Biotech

Drug Trial Radar · NCT02055157

A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia

A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia

Last checked: Nov 20, 2026Latest source record: Jan 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

35

Actual

Start

Jan 13, 2014

Primary completion

Oct 2, 2017

Study completion Oct 2, 2017

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Feb 5, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.

Conditions

  • Achondroplasia

Interventions

  • BMN 111Drug

    BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Summary of Adverse Events During Initial 6-Month PeriodTime frame: Up to Month 6 ± 7 Days
  2. Overall Summary of Adverse Events During Entire Study PeriodTime frame: Up to Month 25 ± 7 Days

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Children's Hospital & Research Center Oakland

    Oakland, California

  • Harbor - UCLA Medical Center

    Torrance, California

  • Ann and Robert H. Lurie Childrens Hospital of Chicago

    Chicago, Illinois

  • Johns Hopkins McKusick - Institute of Genetic Medicine

    Baltimore, Maryland

  • Vanderbilt University

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

  • Murdoch Children's Research Institute

    Parkville, Victoria, Australia

  • Institut Necker

    Paris, France

  • Guys & St. Thomas NHS Foundation Trust Evelina Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.